BASF agrees to sell its optical brightening agent business to Catexel, supporting portfolio optimization and enabling focused growth under new ownership.
BASF has entered into a definitive agreement with Catexel for the divestment of its optical brightening agent business, marking another step in BASF’s ongoing portfolio transformation. Optical brightening agents are essential components used primarily in laundry detergent formulations, where they enhance the appearance of fabrics by improving whiteness and brightness. The business currently operates within BASF’s Care Chemicals division and serves customers globally. While the financial terms of the transaction have not been disclosed, the companies expect the deal to close in the first quarter of 2026, subject to customary regulatory approvals and closing conditions.
The scope of the transaction includes BASF’s entire international optical brightening agent business, encompassing production operations located at the Monthey manufacturing site in Switzerland. Approximately 80 employees associated with the business will transfer as part of the agreement, ensuring continuity of expertise, operational stability, and customer service. The Monthey facility is regarded as a modern, high-quality production site and will form a critical foundation for the future development of the business under its new ownership.
For BASF, the divestment aligns with its broader strategic transformation agenda, known as the “Winning Ways” strategy. This approach focuses on actively managing the company’s portfolio, sharpening strategic priorities, and allocating resources toward businesses with the strongest long-term growth potential. By divesting the optical brightening agent segment, BASF aims to streamline its Care Chemicals portfolio while ensuring the business continues to thrive under an owner fully dedicated to its development.
Commenting on the transaction, Mary Kurian, President of Care Chemicals at BASF, emphasized that the move reflects disciplined portfolio management. She noted that Catexel’s focused ownership and commitment to specialty chemicals will enable the optical brightening agent business to further realize its potential, benefiting customers and employees alike.
Catexel operates as the Care Chemicals platform of the International Chemical Investors Group (ICIG). The company specializes in high-quality specialty chemicals for a wide range of applications, including detergents and cleaning products, personal care formulations, and industrial uses. By acquiring BASF’s optical brightening agent business, Catexel is significantly expanding its portfolio and reinforcing its ambition to provide customers with a broader offering of premium ingredients. The acquisition also strengthens Catexel’s market presence and enhances its position as a long-term, reliable partner for detergent and cleaning product manufacturers worldwide.
Alexander Snell, President and Chief Executive Officer of Catexel, described the acquisition as a key milestone in the company’s growth strategy. He highlighted the importance of the advanced production infrastructure and the experienced Swiss-based team, stating that both will support innovation, operational excellence, and sustainable growth. According to Snell, the transaction underscores Catexel’s commitment to investing in high-performing assets that align with its strategic direction.
Following the divestment, BASF will continue to be one of the world’s leading suppliers and innovators of ingredients for home care as well as industrial and institutional cleaning markets. The company remains focused on delivering advanced solutions that meet evolving customer and sustainability requirements, while optimizing its portfolio to maintain competitiveness and long-term value creation.
